Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BB Biotech – executive interview

BB Biotech – executive interview

BB Biotech — 6 videos in collection

More on this equity

In this interview, we speak to Dr Daniel Koller, portfolio manager at BB Biotech (BION), the Swiss-based investment company listed in Switzerland, Germany and Italy. Dr Koller shares his views on the biotech sector and expands on the following themes:

The sectors ability to outperform the broader equity market as the market moves forward and returns to growth.
The outlook and key risks for the biotech/pharma sector for the remainder of 2023.
Listed versus private companies valuations in the sector.
How BB Biotech is positioned to take advantage of the current situation in the market amid lower valuations.

< Previous
Next >

You may also be interested in these:

Investment Companies

BB Biotech – executive interview
Growth Conf thumbnail (2)

Edison Growth Conference panel – 2024: The year of M&A?

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free